In prostate and bladder cancer, it was reported that IFIT5 was able to promote epithelial–mesenchymal transition and progression, but there is no study reported in lung cancer, so the role of IFIT5 in lung cancer still needs to be explored (61, 62). Here, IFIT5 is linked to urinary bladder cancer.